During my university years in Padua, where I followed in the footsteps of William Harvey (Fig. 1), I was fascinated by the emerging discipline of hepatology. In the 1950s, two discoveries opened the way to understanding the new and evolving entity of chronic hepatitis (CH). First was the observation by the Italian clinicians Fernando de Ritis, Mario Coltorti, and Giuseppe Giusti 1 that serum transaminases (or aminotransferases, for the pedants among you) that once were the sole domain of the cardiologists 2 were elevated in patients with hepatitis. Ironically, cardiologists now find that serum alkaline phosphatase and gamma-glutamyl transferase are useful in assessing coronary artery disease. 3 Second was the almost coincident honing of the technique of liver biopsy by Dr. Giorgio Menghini 4 (Fig. 2). The allure of CH was that it seemed to be the missing link between cirrhosis (which had been known since antiquity) and acute hepatitis.